H.C. Wainwright analyst Brandon Folkes initiated coverage of Traws Pharma (TRAW) with a Buy rating and $8 price target The company’s pipeline is led by two oral antivirals, ratutrelvir in development for COVID-19, and tivoxavir marboxil for seasonal and avian influenza, the analyst tells investors in a research note. The firm believes Traws has the potential to unlock value for shareholders if the company is able to replicate the strong early stage data.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRAW: